<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2017.01826</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>End-Stage Renal Disease Causes Skewing in the TCR V&#x003B2;-Repertoire Primarily within CD8<sup>&#x0002B;</sup> T Cell Subsets</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Huang</surname> <given-names>Ling</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Betjes</surname> <given-names>Michiel G. H.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/189163"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Klepper</surname> <given-names>Mariska</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Langerak</surname> <given-names>Anton W.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/29407"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Baan</surname> <given-names>Carla C.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/51610"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Litjens</surname> <given-names>Nicolle H. R.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x0002A;</xref>
<uri xlink:href="http://frontiersin.org/people/u/233311"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Nephrology and Transplantation</institution>, <addr-line>Rotterdam</addr-line>, <country>Netherlands</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Immunology, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>Rotterdam</addr-line>, <country>Netherlands</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Valquiria Bueno, Federal University of S&#x000E3;o Paulo, Brazil</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Stephen H. Benedict, University of Kansas, United States; Jennifer Ann Juno, University of Melbourne, Australia</p></fn>
<corresp content-type="corresp" id="cor1">&#x0002A;Correspondence: Nicolle H. R. Litjens, <email>n.litjens&#x00040;erasmusmc.nl</email></corresp>
<fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to Inflammation, a section of the journal Frontiers in Immunology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>1826</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>12</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2017 Huang, Betjes, Klepper, Langerak, Baan and Litjens.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Huang, Betjes, Klepper, Langerak, Baan and Litjens</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>A broad T cell receptor (TCR-) repertoire is required for an effective immune response. TCR-repertoire diversity declines with age. End-stage renal disease (ESRD) patients have a prematurely aged T cell system which is associated with defective T cell-mediated immunity. Recently, we showed that ESRD may significantly skew the TCR V&#x003B2;-repertoire. Here, we assessed the impact of ESRD on the TCR V&#x003B2;-repertoire within different T cell subsets using a multiparameter flow-cytometry-based assay, controlling for effects of aging and CMV latency. Percentages of 24 different TCR V&#x003B2;-families were tested in circulating naive and memory T cell subsets of 10 ESRD patients and 10 age- and CMV-serostatus-matched healthy individuals (HI). The Gini-index, a parameter used in economics to describe the distribution of income, was calculated to determine the extent of skewing at the subset level taking into account frequencies of all 24 TCR V&#x003B2;-families. In addition, using HI as reference population, the differential impact of ESRD was assessed on clonal expansion at the level of an individual TCR V&#x003B2;-family. CD8<sup>&#x0002B;</sup>, but not CD4<sup>&#x0002B;</sup>, T cell differentiation was associated with higher Gini-TCR indices. Gini-TCR indices were already significantly higher for different CD8<sup>&#x0002B;</sup> memory T cell subsets of younger ESRD patients compared to their age-matched HI. ESRD induced expansions of not one TCR V&#x003B2;-family in particular and expansions were predominantly observed within the CD8<sup>&#x0002B;</sup> T cell compartment. All ESRD patients had expanded TCR V&#x003B2;-families within total CD8<sup>&#x0002B;</sup> T cells and the median (IQ range) number of expanded TCR V&#x003B2;-families/patient amounted to 2 (1&#x02013;4). Interestingly, ESRD also induced clonal expansions of TCR V&#x003B2;-families within naive CD8<sup>&#x0002B;</sup> T cells as 8 out of 10 patients had expanded TCR V&#x003B2;-families. The median (IQ range) number of expanded families/patient amounted to 1 (1&#x02013;1) within naive CD8<sup>&#x0002B;</sup> T cells. In conclusion, loss of renal function skews the TCR V&#x003B2;-repertoire already in younger patients by inducing expansions of different TCR V&#x003B2;-families within the various T cell subsets, primarily affecting the CD8<sup>&#x0002B;</sup> T cell compartment. This skewed TCR V&#x003B2;-repertoire may be associated with a less broad and diverse T cell-mediated immunity.</p>
</abstract>
<kwd-group>
<kwd>TCR-repertoire</kwd>
<kwd>T cell subsets</kwd>
<kwd>end-stage renal disease</kwd>
<kwd>ageing (aging)</kwd>
<kwd>CMV-latency</kwd>
</kwd-group>
<contract-num rid="cn01">201307720043</contract-num>
<contract-sponsor id="cn01">China Scholarship Council<named-content content-type="fundref-id">10.13039/501100004543</named-content></contract-sponsor>
<counts>
<fig-count count="4"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="52"/>
<page-count count="10"/>
<word-count count="6670"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="introduction">
<title>Introduction</title>
<p>End-stage renal disease (ESRD) patients have a decreased vaccination efficacy (<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>), an increased susceptibility for infection (<xref ref-type="bibr" rid="B5">5</xref>&#x02013;<xref ref-type="bibr" rid="B7">7</xref>) and a higher risk for the development of tumors (<xref ref-type="bibr" rid="B8">8</xref>&#x02013;<xref ref-type="bibr" rid="B11">11</xref>). Loss of renal function is associated with a prematurely aged T cell system (<xref ref-type="bibr" rid="B12">12</xref>), most likely caused by the uremia-induced proinflammatory environment (<xref ref-type="bibr" rid="B13">13</xref>). These uremia-induced effects on T cells are expressed as a decline in thymic output, a severe depletion of naive T cell compartment, a shift to more highly differentiated memory T cell subsets, attrition of T cell telomeres (<xref ref-type="bibr" rid="B14">14</xref>) and a defective T cell receptor (TCR)-induced ERK phosphorylation (<xref ref-type="bibr" rid="B15">15</xref>).</p>
<p>A broad TCR-repertoire capable of recognizing a wide range of foreign antigens is crucial for adequate T cell-mediated immune responses (<xref ref-type="bibr" rid="B16">16</xref>). Most TCRs consist of an &#x003B1; and &#x003B2; chain and each chain is composed of a variable (V) and a constant (C) region (<xref ref-type="bibr" rid="B17">17</xref>). The TCR V&#x003B2;-repertoire can be assessed using several approaches such as gene scan spectratyping <italic>via</italic> a DNA-based PCR (<xref ref-type="bibr" rid="B18">18</xref>), V&#x003B2;-family phenotyping by flow-cytometry (<xref ref-type="bibr" rid="B19">19</xref>&#x02013;<xref ref-type="bibr" rid="B21">21</xref>), and assessment of clonal diversity <italic>via</italic> next generation sequencing (NGS) (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>). Gene scan spectratyping of the TCR V&#x003B2;-repertoire is at best a semiquantitative measurement. Both flow-cytometry and NGS result in a more accurate quantitative assessment of the TCR V&#x003B2;-repertoire. As NGS is more labor-intensive and sorting of highly pure T cells or their subsets is required, many researchers prefer to use flow-cytometry. Flow-cytometry allows for measuring percentages of TCR V&#x003B2;-families at the T cell-subset level obviating the need for cell sorting.</p>
<p>We recently examined the TCR V&#x003B2;-repertoire in ESRD patients using multiplex DNA-based spectratyping. We showed ESRD to significantly and independently skew the TCR V&#x003B2;-repertoire in older individuals and this skewing was predominantly present within the CD8<sup>&#x0002B;</sup> memory T cell compartment (<xref ref-type="bibr" rid="B24">24</xref>). However, details of this skewed TCR V&#x003B2;-repertoire in ESRD patients are still lacking and quantitative data related to the impact of ESRD on TCR V&#x003B2;-repertoire in the various T cell populations is rare.</p>
<p>During aging, the TCR V&#x003B2;-repertoire has been reported to contract (<xref ref-type="bibr" rid="B25">25</xref>). Aging is associated with a decline in the naive T cell compartment which possess the broadest TCR repertoire (<xref ref-type="bibr" rid="B26">26</xref>), and a shift toward memory T cells, developing upon encountering of an antigen and having a skewed repertoire toward particular specificities (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>). The prevalence of CMV-seropositivity is high amongst ESRD patients, varying from 30 to 100%, depending on socioeconomic and ethnic background (<xref ref-type="bibr" rid="B29">29</xref>). CMV latency profoundly affects circulating T cells resembling features of aging, including increased frequencies of more differentiated memory T cells (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>) and loss of telomere length (<xref ref-type="bibr" rid="B32">32</xref>). CMV latency may also induce contraction of the TCR V&#x003B2;-repertoire as it induces expansion of CMV-specific T cells immunocompetent donors (<xref ref-type="bibr" rid="B33">33</xref>) and these CMV-specific clones are stably maintained for 5&#x02009;years (<xref ref-type="bibr" rid="B34">34</xref>). Thus, TCR V&#x003B2;-repertoire diversity may be affected by various factors.</p>
<p>In this study, we assessed the TCR V&#x003B2;-repertoire diversity within different T cell subsets in ESRD patients using a flow-cytometry-based taking into account the effects of aging and CMV latency.</p>
</sec>
<sec id="S2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="S2-1">
<title>Study Population</title>
<p>A cohort of 10 stable ESRD patients, either younger individuals (<italic>n</italic>&#x02009;&#x0003D;&#x02009;5, age&#x02009;&#x0003C;&#x02009;45&#x02009;years) or older individuals (<italic>n</italic>&#x02009;&#x0003D;&#x02009;5, age&#x02009;&#x02265;&#x02009;65&#x02009;years) with an oligoclonal TCR V&#x003B2;-repertoire, as determined by DNA-based spectratyping earlier (<xref ref-type="bibr" rid="B24">24</xref>) were studied in more detail at the T cell-subset level using a flow-cytometry based assay for TCR V&#x003B2;-repertoire analysis. Patients having a glomerular filtration rate below 15&#x02009;mL/min and either or not receiving renal replacement therapy (RRT) were included. Patients were excluded from the study when having a bacterial or viral infection, malignancy, a previous transplantation or taking immunosuppressive medication (except for glucocorticoids). The patient data are compared to those generated from 10 age- and CMV-matched healthy individuals (HIs) with a polyclonal TCR V&#x003B2;-repertoire, as determined by DNA-based spectratyping (<xref ref-type="bibr" rid="B24">24</xref>). Lithium-heparinized blood was drawn from ESRD patients and HI. Written informed consent was obtained from all individuals included. The study was approved by the local medical ethical committee (METC number: 2012-022) and conducted according to the principles of Declaration of Helsinki and in compliance with International Conference on Harmonization/Good Clinical Practice regulations.</p>
</sec>
<sec id="S2-2">
<title>Sample Preparation</title>
<p>Peripheral blood mononuclear cells (PBMCs) were isolated from 35&#x02009;mL of lithium-heparinized blood by density centrifugation as described previously (<xref ref-type="bibr" rid="B35">35</xref>) and then frozen at 10&#x02009;&#x000D7;&#x02009;10<sup>6</sup> PBMC per vial at &#x02212;190&#x000B0;C until further use.</p>
<p>Cryopreserved PBMCs (1 vial of 10&#x02009;&#x000D7;&#x02009;10<sup>6</sup> PBMCs) were thawed, counted, washed and resuspended in Isoflow&#x02122; Sheath Fluid (Beckman Coulter B.V., Woerden, Netherlands). The PBMCs were stained with Brilliant Violet 510-labeled anti-CD3 (BioLegend, Uithoorn, Netherlands), Alexa Fluor (AF)700-labeled anti-CD4 (Beckman Coulter B.V.) and Allophycocyanin (APC)-Cy7-labeled anti-CD8 (BioLegend) to identify CD4<sup>&#x0002B;</sup> and CD8<sup>&#x0002B;</sup> within CD3<sup>&#x0002B;</sup> T cells. ECD-labeled anti-CD45RO (Beckman Coulter B.V.), PE-Cy7-labeled anti-CCR7 (BD, Erembodegem, Belgium), V450-labeled anti-CD31 (BD; clone WM59), peridinin chlorophyll-A protein-Cy5.5-labeled anti-CD28 (BD) and APC-labeled anti-CD57 (BioLegend) as well as fluorescence minus one controls were used to appropriately identify the different T cell subsets (illustrated in Figures S1B&#x02013;D in Supplementary Material). As shown in Figure S1B in Supplementary Material, CCR7 and CD45RO are used to distinguish the different naive and memory T cell subsets, i.e., naive (CD45RO<sup>&#x02212;</sup>CCR7<sup>&#x0002B;</sup>), central memory (CM, CD45RO<sup>&#x0002B;</sup>CCR7<sup>&#x0002B;</sup>), effector memory (EM, CD45RO<sup>&#x0002B;</sup>CCR7<sup>&#x02212;</sup>), and terminally differentiated effector memory CD45RA<sup>&#x0002B;</sup> T cells subsets (EMRA, CD45RO<sup>&#x02212;</sup>CCR7<sup>&#x02212;</sup>). CD31-expression within naive T cells (Figure S1C in Supplementary Material) identifies T cells that recently have left the thymus, also referred to as recent thymic emigrants (RTEs) (<xref ref-type="bibr" rid="B36">36</xref>). Loss of CD28 (CD28<sup>&#x02212;</sup> T cells) and gain of CD57 (CD57<sup>&#x0002B;</sup> T cells) expression is observed in relation to increased replicative history (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>) and allows for identification of more differentiated T cells (Figure S1D in Supplementary Material).</p>
<p>Subsequently, the cell suspension was divided into eight tubes (100&#x02009;&#x003BC;L/tube) labeled A-H, corresponding to the different antibody cocktails to stain for the 24 TCR V&#x003B2;-families (IOTest<sup>&#x000AE;</sup> Beta Mark TCR V beta repertoire kit, Beckman Coulter B.V.). Each cocktail contains antibodies directed to three different V&#x003B2;-families, i.e., one is fluorescein isothiocyanate (FITC-), one is PE-labeled and one is labeled with both FITC and PE. Table <xref ref-type="table" rid="T1">1</xref> shows the description of the antibodies directed to the different TCR V&#x003B2;-families in tube A to H. A typical example of the proportions of several TCR V&#x003B2;-families within CD3<sup>&#x0002B;</sup> T cells from tube A, tube B and tube C is depicted in Figure S1A in Supplementary Material, the last three plots.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>TCR V&#x003B2;-families in tube A-H.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Tube</th>
<th valign="top" align="left">V&#x003B2; family</th>
<th valign="top" align="left">Fluorochrome</th>
<th valign="top" align="left">Clone</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="3">A</td>
<td align="left" valign="top">V&#x003B2; 5.3</td>
<td align="left" valign="top">PE</td>
<td align="left" valign="top">3D11</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 3</td>
<td align="left" valign="top">FITC</td>
<td align="left" valign="top">CH92</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 7.1</td>
<td align="left" valign="top">PE&#x02009;&#x0002B;&#x02009;FITC</td>
<td align="left" valign="top">ZOE</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="3">B</td>
<td align="left" valign="top">V&#x003B2; 9</td>
<td align="left" valign="top">PE</td>
<td align="left" valign="top">FIN9</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 16</td>
<td align="left" valign="top">FITC</td>
<td align="left" valign="top">TAMAYA1.2</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 17</td>
<td align="left" valign="top">PE&#x02009;&#x0002B;&#x02009;FITC</td>
<td align="left" valign="top">E17.5F3</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="3">C</td>
<td align="left" valign="top">V&#x003B2; 18</td>
<td align="left" valign="top">PE</td>
<td align="left" valign="top">BA62.6</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 20</td>
<td align="left" valign="top">FITC</td>
<td align="left" valign="top">ELL1.4</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 5.1</td>
<td align="left" valign="top">PE&#x02009;&#x0002B;&#x02009;FITC</td>
<td align="left" valign="top">IMMU157</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="3">D</td>
<td align="left" valign="top">V&#x003B2; 13.1</td>
<td align="left" valign="top">PE</td>
<td align="left" valign="top">IMMU222</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 8</td>
<td align="left" valign="top">FITC</td>
<td align="left" valign="top">56C5.2</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 13.6</td>
<td align="left" valign="top">PE&#x02009;&#x0002B;&#x02009;FITC</td>
<td align="left" valign="top">JU74.3</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="3">E</td>
<td align="left" valign="top">V&#x003B2; 5.2</td>
<td align="left" valign="top">PE</td>
<td align="left" valign="top">36213</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 12</td>
<td align="left" valign="top">FITC</td>
<td align="left" valign="top">VER2.32</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 2</td>
<td align="left" valign="top">PE&#x02009;&#x0002B;&#x02009;FITC</td>
<td align="left" valign="top">MPB2D5</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="3">F</td>
<td align="left" valign="top">V&#x003B2; 23</td>
<td align="left" valign="top">PE</td>
<td align="left" valign="top">AF23</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 21.3</td>
<td align="left" valign="top">FITC</td>
<td align="left" valign="top">IG125</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 1</td>
<td align="left" valign="top">PE&#x02009;&#x0002B;&#x02009;FITC</td>
<td align="left" valign="top">BL37.2</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="3">G</td>
<td align="left" valign="top">V&#x003B2; 11</td>
<td align="left" valign="top">PE</td>
<td align="left" valign="top">C21</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 14</td>
<td align="left" valign="top">FITC</td>
<td align="left" valign="top">CAS1.1.3</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 22</td>
<td align="left" valign="top">PE&#x02009;&#x0002B;&#x02009;FITC</td>
<td align="left" valign="top">IMMU546</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="3">H</td>
<td align="left" valign="top">V&#x003B2; 13.2</td>
<td align="left" valign="top">PE</td>
<td align="left" valign="top">H132</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 7.2</td>
<td align="left" valign="top">FITC</td>
<td align="left" valign="top">ZIZOU4</td>
</tr>
<tr>
<td align="left" valign="top">V&#x003B2; 4</td>
<td align="left" valign="top">PE&#x02009;&#x0002B;&#x02009;FITC</td>
<td align="left" valign="top">WJF24</td>
</tr>
</tbody>
</table>
<table-wrap-foot><p><italic>Detailed information with respect to the different TCR V&#x003B2;-family antibodies in tube A-H, labels and clones (IOTest<sup>&#x000AE;</sup> Beta Mark TCR V beta repertoire kit, Beckman Coulter)</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>The samples were measured on a Navios flow cytometer (10-color configuration; Beckman Coulter B.V.) and at least 0.5 million CD3<sup>&#x0002B;</sup> T cells were acquired for each tube. Data were analyzed by Kaluza&#x02122; software (Beckman Coulter B.V.). The number of events acquired for a specific T cell subset needed to be more than 100 to allow for reliable analysis of frequencies of TCR V&#x003B2;-families within this population. The only subset that did not meet this criterion was the EMRA population within the CD4<sup>&#x0002B;</sup> T cells.</p>
</sec>
<sec id="S2-3">
<title>Gini-TCR Index and Calculation of Expanded TCR V&#x003B2;&#x02212;Families</title>
<p>The Gini index is used to describe the distribution of income in economic statistics. As the distribution of TCR V&#x003B2;&#x02212;families shows similarities to that of income, the Gini index can also be applied in TCR V&#x003B2;-repertoire analysis by flow-cytometry. It has already been used in TCR-sequencing studies (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>), and was recently also introduced as an accurate and reliable way for analyzing TCR V&#x003B2;-repertoire data obtained by flow-cytometry (<xref ref-type="bibr" rid="B41">41</xref>). The TCR (V&#x003B2;)-Gini index with scores ranging from low to high indicates TCR V&#x003B2;-families from equal distribution (broad repertoire; i.e., low score) to unequal distribution (skewed repertoire; i.e., high score). A Microsoft excel file allowing for automatic calculation of the Gini-TCR index using percentages of 24 TCR-V&#x003B2; families is provided in the supporting file (<xref ref-type="bibr" rid="B41">41</xref>).</p>
<p>An expansion in a TCR V&#x003B2;-family in ESRD patients is defined as a frequency above the mean percentage&#x02009;&#x0002B;&#x02009;2 times the SD of a certain TCR V&#x003B2;-family obtained using the HI as reference population. By using this approach, finding an expansion by chance is lower than 2.5%.</p>
</sec>
<sec id="S2-4">
<title>Statistical Analyses</title>
<p>Gini-TCR indices or median number of expanded TCR V&#x003B2;-families/individual between two different T cell subsets within individuals were compared with Wilcoxon signed rank test and Friedman test followed by Dunn&#x02019;s multiple comparison <italic>T</italic>-test was used for comparing more than two different T cell subsets. Trend analyses were performed using two-way ANOVA, comparing different subsets between individuals or CD4<sup>&#x0002B;</sup> and CD8<sup>&#x0002B;</sup> T cells. In addition, the effect of ESRD with respect to numbers of expanded TCR V&#x003B2;-families within different T cell subsets is done using Fisher&#x02019;s exact test. Two-sided <italic>P</italic>&#x02013;values &#x0003C;0.05 were considered statistically significant. All statistical analyses were performed with GraphPad Prism 5.</p>
</sec>
</sec>
<sec id="S3">
<title>Results</title>
<sec id="S3-1">
<title>Study Population</title>
<p>Detailed information of the study population is given in Table <xref ref-type="table" rid="T2">2</xref>. Ten ESRD patients (5 younger individuals: age 20&#x02013;29&#x02009;years and 5 older individuals: age 65&#x02013;73&#x02009;years) and 10 age-matched HI (5 younger individuals age 26&#x02013;42&#x02009;years and 5 older individuals: age 65&#x02013;73&#x02009;years) were recruited into this study. Sixty percent of the ESRD and HI study population is CMV-seropositive. Seven out of 10 ESRD patients received RRT.</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Demographic and clinical characteristics of the study population.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left"/>
<th valign="top" align="center">Healthy individuals</th>
<th valign="top" align="center">ESRD patients</th>
<th valign="top" align="center"><italic>P</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Number of individuals</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Age (years; range)</td>
</tr>
<tr>
<td align="left" valign="top">younger group (&#x0003C;45&#x02009;years)</td>
<td align="center" valign="top">36 (26&#x02013;42)</td>
<td align="center" valign="top">28 (20&#x02013;29)</td>
<td align="center" valign="top">0.06</td>
</tr>
<tr>
<td align="left" valign="top">older group (&#x0003E;65&#x02009;years)</td>
<td align="center" valign="top">68 (65&#x02013;73)</td>
<td align="center" valign="top">70 (65&#x02013;73)</td>
<td align="center" valign="top">0.92</td>
</tr>
<tr>
<td align="left" valign="top">Sex (% male)</td>
<td align="center" valign="top">60</td>
<td align="center" valign="top">40</td>
<td align="center" valign="top">0.66</td>
</tr>
<tr>
<td align="left" valign="top">CMV IgG serostatus (% pos)</td>
<td align="center" valign="top">60</td>
<td align="center" valign="top">60</td>
<td align="center" valign="top">1.00</td>
</tr>
<tr>
<td align="left" valign="top">RRT (%)</td>
<td align="center" valign="top">n.a.</td>
<td align="center" valign="top">70</td>
<td align="center" valign="top">n.a.</td>
</tr>
<tr>
<td align="left" valign="top">Duration of RRT (months; median/range)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">20 (7&#x02013;68)</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Hemodialysis (%)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">85.7</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Peritoneal dialysis (%)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">14.3</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="4">Underlying kidney disease</td>
</tr>
<tr>
<td align="left" valign="top">Primary glomerulopathy (%)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">20</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Diabetic nephropathy (%)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">30</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Reflux nephropathy (%)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">10</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Polycystic kidney disease (%)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">20</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Lupus nephritis (%)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">10</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Unknown (%)</td>
<td align="center" valign="top"/>
<td align="center" valign="top">10</td>
<td align="center" valign="top"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>ESRD, end-stage renal disease; CMV, cytomegalovirus; pos, positive; RRT, renal replacement therapy; n.a., not applicable</italic>.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="S3-2">
<title>Gini-TCR Indices Increase with T Cell Differentiation</title>
<p>Naive T cells expressing CD31 are considered to be RTEs and the least-differentiated T cell subset. In ESRD patients, CD31-expressing naive T cells tended to or have a lower Gini-TCR index when compared to their CD31<sup>&#x02212;</sup> counterparts within CD4<sup>&#x0002B;</sup> (Figure <xref ref-type="fig" rid="F1">1</xref>B) and CD8<sup>&#x0002B;</sup> T cells (Figure <xref ref-type="fig" rid="F1">1</xref>D), respectively. For HI, a significant lower Gini-TCR index was only observed for CD31-expressing naive CD8<sup>&#x0002B;</sup> (Figure <xref ref-type="fig" rid="F1">1</xref>C) but not CD4<sup>&#x0002B;</sup> (Figure <xref ref-type="fig" rid="F1">1</xref>A) T cells when compared to CD31<sup>&#x02212;</sup> naive T cells. Furthermore, a T cell differentiation-associated increase in Gini-TCR indices was noted for CD8<sup>&#x0002B;</sup> (Figures <xref ref-type="fig" rid="F1">1</xref>G,H), but not CD4<sup>&#x0002B;</sup> (Figures <xref ref-type="fig" rid="F1">1</xref>E,F), T cells. The median value (IQ range) increased significantly (<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.001) from 36.5 (33.7&#x02013;37) and 35.5 (33.8&#x02013;37.9) in naive T cells to 49 (43&#x02013;64.6) and 52.4 (44.9&#x02013;72.8) in the highly differentiated EMRA CD8<sup>&#x0002B;</sup> T cells for HI and ESRD patients, respectively.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Gini-T cell receptor (TCR) indices for different T cell subsets. The different Gini-TCR indices are depicted for healthy individual (HI) <bold>(A,C,E,G)</bold> and end-stage renal disease (ESRD) patients <bold>(B,D,F,H)</bold>. First, the Gini-TCR indices for recent thymic emigrant (CD31<sup>&#x0002B;</sup> naive) and CD31<sup>&#x02212;</sup> naive CD4<sup>&#x0002B;</sup> <bold>(A,B)</bold> and CD8<sup>&#x0002B;</sup> T <bold>(C,D)</bold> cells are given, respectively. Next, the differentiation-associated effects on Gini-TCR indices are depicted for CD4<sup>&#x0002B;</sup> <bold>(E,F)</bold> and CD8<sup>&#x0002B;</sup> <bold>(G,H)</bold> T cell subsets, including naive, central memory, effector memory, and terminally differentiated effector memory CD45RA<sup>&#x0002B;</sup> (EMRA) T cells. &#x0002A;, &#x0002A;&#x0002A;, and &#x0002A;&#x0002A;&#x0002A; reflect <italic>P</italic>-values &#x0003C;0.05, 0.01, and 0.001, respectively. Data from 10 HI and 10 ESRD patients are given as median with interquartile range.</p></caption>
<graphic xlink:href="fimmu-08-01826-g001.tif"/>
</fig>
</sec>
<sec id="S3-3">
<title>ESRD Patients Have Increased Gini-TCR Indices within Memory CD8<sup>&#x0002B;</sup> T Cell Subsets</title>
<p>We next analyzed the influence of ESRD, aging, and CMV latency on skewing of the TCR V&#x003B2;-repertoire by comparing Gini-TCR indices for different T cell subsets including total CD3<sup>&#x0002B;</sup> T cells, as well as naive, CD31<sup>&#x0002B;</sup> naive, total memory (MEM), CM, EM, EMRA, CD28<sup>&#x02212;</sup>, and CD57<sup>&#x0002B;</sup> populations within both the CD4<sup>&#x0002B;</sup> and CD8<sup>&#x0002B;</sup> T cell subsets. ESRD effects with respect to Gini-TCR indices were limited to the CD8<sup>&#x0002B;</sup> T cell compartment as it tended to induce higher Gini-TCR indices (<italic>P</italic>&#x02009;&#x0003D;&#x02009;0.06) in CD8<sup>&#x0002B;</sup> memory T cells when compared to HI (Figure <xref ref-type="fig" rid="F2">2</xref>A). The median (IQ range) value for Gini-TCR index in CD8<sup>&#x0002B;</sup> memory T cells amounted to 48.4 (45.8&#x02013;63.3) and 43.8 (41.1&#x02013;51.2) for ESRD patients and HI, respectively. Younger (Figure <xref ref-type="fig" rid="F2">2</xref>B), but not older (Figure <xref ref-type="fig" rid="F2">2</xref>C), ESRD patients had significantly higher Gini-TCR indices within the CD8<sup>&#x0002B;</sup> CM (<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05), EM (<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05) and CD57<sup>&#x0002B;</sup> T cell compartment when compared to age-matched HI. The median (IQ range) for Gini-TCR in CD8<sup>&#x0002B;</sup> CM, EM and CD57<sup>&#x0002B;</sup> T cells amounted to 47.4 (40.8&#x02013;54.2) versus 35.3 (34.0&#x02013;39.2), 54.4 (49.6&#x02013;68.5) versus 43.7 (42.4&#x02013;50.8) and 77.6 (65.8&#x02013;78.4) versus 59.2 (57.2&#x02013;67.1) for younger ESRD patients versus younger HI.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>Effect of end-stage renal disease (ESRD) on Gini-T cell receptor (TCR) indices of CD8<sup>&#x0002B;</sup> T cell subsets. In <bold>(A)</bold>, the median and IQ range of the Gini-TCR indices for healthy individuals (<italic>N</italic>&#x02009;&#x0003D;&#x02009;10) and ESRD patients (<italic>N</italic>&#x02009;&#x0003D;&#x02009;10) for different CD8<sup>&#x0002B;</sup> T cell subsets is depicted, whereas in <bold>(B,C)</bold> those for the younger and older group (<italic>N</italic>&#x02009;&#x0003D;&#x02009;5) are given, respectively. <italic>P</italic> value: &#x0002A;&#x0003C;0.05.</p></caption>
<graphic xlink:href="fimmu-08-01826-g002.tif"/>
</fig>
<p>The following results, describing Tables S1 and S2 in Supplementary Material need to be interpreted with caution as the <italic>P</italic>-values were not adjusted for the number of parameters compared.</p>
<p>Aging effects were not visible when comparing Gini-TCR indices for the different T cell subsets between younger and older ESRD patients (Table S1 in Supplementary Material). In HI, aging effects were confined to the CD8<sup>&#x0002B;</sup> T cell compartment and an aging-related increasing trend in Gini-TCR index was observed for CD8<sup>&#x0002B;</sup> CM T cells (<italic>P</italic>&#x02009;&#x0003D;&#x02009;0.06), as the median (IQ range) for Gini-TCR amounted to 40.1 (39.1&#x02013;44.1) in older HI versus 35.3 (34.0&#x02013;39.2) in younger HI. An increased Gini-TCR index (<italic>P</italic>&#x02009;&#x0003D;&#x02009;0.03) was observed for older HI, within CD8<sup>&#x0002B;</sup>CD28<sup>&#x02212;</sup> T cells (Table S1 in Supplementary Material). The median (IQ range) value for Gini-TCR in CD8<sup>&#x0002B;</sup>CD28<sup>&#x02212;</sup> T cells amounted to 42.0 (40.6&#x02013;47.4) versus 57.8 (43.7&#x02013;63.7) for younger and older HI, respectively.</p>
<p>CMV latency did not significantly affect Gini-TCR indices apart from a CMV-related increasing trend within CD4<sup>&#x0002B;</sup>CD57<sup>&#x0002B;</sup> T cells (<italic>P</italic>&#x02009;&#x0003D;&#x02009;0.07) of HI, but not ESRD patients, i.e., the median (IQ range) Gini-TCR index amounted to 67.0 (57.4&#x02013;72.2) for CMV-seropositive HI versus 45.6 (35.5&#x02013;58.0) for CMV-seronegative ones (Table S2 in Supplementary Material). No differences were observed when comparing CMV-seronegative and CMV-seropositive ESRD patients to their CMV-serostatus matched HI with respect to Gini-TCR indices for the different T cell subsets (data not shown).</p>
</sec>
<sec id="S3-4">
<title>Clonal Expansions of TCR V&#x003B2;-Families in Different T Cell Subsets</title>
<p>Apart from characterizing the impact of ESRD on Gini-TCR indices for the different T cell subsets, we also evaluated the impact of ESRD on clonal expansions of TCR V&#x003B2;-families by comparing frequencies to the average&#x02009;&#x0002B;&#x02009;2SD obtained using HI as reference population. Figure <xref ref-type="fig" rid="F3">3</xref> shows a typical example of expanded TCR V&#x003B2;-families within CD8<sup>&#x0002B;</sup> memory T cells of ESRD patients.</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>Expansions of T cell receptor (TCR) V&#x003B2;-families within CD8<sup>&#x0002B;</sup> memory T cells from end-stage renal disease (ESRD) patients. Boxes and error bars represent the mean and 95% confidence interval (mean&#x02009;&#x000B1;&#x02009;2SD) of 24 TCR-V&#x003B2; families from 10 healthy individuals (HI). Red dots correspond to expanded TCR V&#x003B2;-families from ESRD patients (frequencies&#x02009;&#x0003E;&#x02009;mean&#x02009;&#x0002B;&#x02009;2SD from HI).</p></caption>
<graphic xlink:href="fimmu-08-01826-g003.tif"/>
</fig>
<p>Clonal expansions of TCR V&#x003B2;-families were observed within the CD3<sup>&#x0002B;</sup> T cells in 7 out of 10 ESRD patients (Table <xref ref-type="table" rid="T3">3</xref>). Half versus all of the ESRD patients showed expanded TCR V&#x003B2;-families within CD4<sup>&#x0002B;</sup> and CD8<sup>&#x0002B;</sup> T cells (<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05), respectively. The median (IQ range) number of expanded TCR V&#x003B2;-families per patient amounted to 1 (0&#x02013;2) and 2 (1&#x02013;4) families for CD4<sup>&#x0002B;</sup> and CD8<sup>&#x0002B;</sup> T cells (<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05), respectively (Figure <xref ref-type="fig" rid="F4">4</xref>A). Interestingly, expansions were also detected within the naive T cell compartment, as 3 out of 10 and 8 out of 10 patients had expansions of TCR V&#x003B2;-families within the naive CD4<sup>&#x0002B;</sup> and CD8<sup>&#x0002B;</sup> T cell compartment, respectively (Table <xref ref-type="table" rid="T3">3</xref>). Most clonal expansions were observed within the (more differentiated) memory CD8<sup>&#x0002B;</sup> T cell subsets (Figure <xref ref-type="fig" rid="F4">4</xref>A). The median (IQ range) number of expanded TCR V&#x003B2;-families amounted to 1 (1&#x02013;1) versus 2 (2&#x02013;4) for naive and memory CD8<sup>&#x0002B;</sup> T cells, respectively (<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05). Moreover, ESRD affected different TCR V&#x003B2;-families as illustrated in Figure <xref ref-type="fig" rid="F3">3</xref> for CD8<sup>&#x0002B;</sup> memory T cells. ESRD induced expansions within both younger (Figure <xref ref-type="fig" rid="F4">4</xref>B) and older (Figure <xref ref-type="fig" rid="F4">4</xref>C) ESRD patients when compared to their age-matched HI.</p>
<table-wrap position="float" id="T3">
<label>Table 3</label>
<caption><p>Effect of ESRD on expansions of TCR V&#x003B2;-families.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left"/>
<th valign="top" align="center">&#x00023; of ESRD patients with/without expansions</th>
<th valign="top" align="center">Median &#x00023; of expanded TCR V&#x003B2;-families (IQ range)</th>
<th valign="top" align="center">Total &#x00023; of expanded TCR V&#x003B2;-families</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">CD3<sup>&#x0002B;</sup></td>
<td align="center" valign="top">7/3</td>
<td align="center" valign="top">1 (0&#x02013;2)</td>
<td align="center" valign="top">15</td>
</tr>
<tr>
<td align="left" valign="top">CD4<sup>&#x0002B;</sup></td>
<td align="center" valign="top">5/5</td>
<td align="center" valign="top">1 (0&#x02013;2)</td>
<td align="center" valign="top">10</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;CD31<sup>&#x0002B;</sup> naive</td>
<td align="center" valign="top">6/4</td>
<td align="center" valign="top">1 (0&#x02013;1)</td>
<td align="center" valign="top">9</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Naive</td>
<td align="center" valign="top">3/7</td>
<td align="center" valign="top">0 (0&#x02013;1)</td>
<td align="center" valign="top">5</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;MEM</td>
<td align="center" valign="top">9/1</td>
<td align="center" valign="top">1 (1&#x02013;3)</td>
<td align="center" valign="top">16</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;CM</td>
<td align="center" valign="top">6/4</td>
<td align="center" valign="top">1 (0&#x02013;2)</td>
<td align="center" valign="top">11</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;EM</td>
<td align="center" valign="top">6/4</td>
<td align="center" valign="top">1 (0&#x02013;2)</td>
<td align="center" valign="top">13</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;CD28<sup>&#x02212;</sup></td>
<td align="center" valign="top">9/1</td>
<td align="center" valign="top">1 (1&#x02013;1)</td>
<td align="center" valign="top">12</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;CD57<sup>&#x0002B;</sup></td>
<td align="center" valign="top">9/1</td>
<td align="center" valign="top">1 (0&#x02013;2)</td>
<td align="center" valign="top">11</td>
</tr>
<tr>
<td align="left" valign="top">CD8<sup>&#x0002B;</sup></td>
<td align="center" valign="top">10/0</td>
<td align="center" valign="top">2 (1&#x02013;4)</td>
<td align="center" valign="top">26</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;CD31<sup>&#x0002B;</sup> naive</td>
<td align="center" valign="top">7/3</td>
<td align="center" valign="top">1 (0&#x02013;2)</td>
<td align="center" valign="top">15</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;Naive</td>
<td align="center" valign="top">8/2</td>
<td align="center" valign="top">1 (1&#x02013;1)</td>
<td align="center" valign="top">12</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;MEM</td>
<td align="center" valign="top">10/0</td>
<td align="center" valign="top">2 (2&#x02013;4)</td>
<td align="center" valign="top">28</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;CM</td>
<td align="center" valign="top">7/3</td>
<td align="center" valign="top">2 (0&#x02013;3)</td>
<td align="center" valign="top">20</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;EM</td>
<td align="center" valign="top">9/1</td>
<td align="center" valign="top">4 (2&#x02013;4)</td>
<td align="center" valign="top">32</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;EMRA</td>
<td align="center" valign="top">10/0</td>
<td align="center" valign="top">2 (1&#x02013;3)</td>
<td align="center" valign="top">26</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;CD28<sup>&#x02212;</sup></td>
<td align="center" valign="top">10/0</td>
<td align="center" valign="top">3 (1&#x02013;3)</td>
<td align="center" valign="top">28</td>
</tr>
<tr>
<td align="left" valign="top">&#x02003;CD57<sup>&#x0002B;</sup></td>
<td align="center" valign="top">9/1</td>
<td align="center" valign="top">3 (1&#x02013;4)</td>
<td align="center" valign="top">25</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p>End-stage renal disease effect on T cell receptor (TCR) V&#x003B2;-families within T cell subsets. Using healthy individual (HI) (<italic>N</italic>&#x02009;&#x0003D;&#x02009;10) as a reference population, we evaluated the number of TCR V&#x003B2;-families that were expanded per patient for a T cell subset (frequency of a TCR V&#x003B2;-family exceeding the mean&#x02009;&#x0002B;&#x02009;2SD value obtained for HI) <bold>(A)</bold>. In <bold>(B,C)</bold>, the median (IQ range) of expansions per younger and older patient for a T cell subset is depicted using the younger (<italic>N</italic>&#x02009;&#x0003D;&#x02009;5) and older HI (<italic>N</italic>&#x02009;&#x0003D;&#x02009;5) as a reference, respectively. The open bars represent the median and IQ range for the different CD4<sup>&#x0002B;</sup> T cell subsets, whereas the closed bars represent that for the different CD8<sup>&#x0002B;</sup> T cell subsets.</p></caption>
<graphic xlink:href="fimmu-08-01826-g004.tif"/>
</fig>
</sec>
</sec>
<sec id="S4" sec-type="discussion">
<title>Discussion</title>
<p>The main finding of this study is that the multiparameter flow-cytometry-based approach for evaluating the skewed TCR V&#x003B2;-repertoire diversity in ESRD patients showed that TCR skewing can be observed primarily in CD8<sup>&#x0002B;</sup> T cell subsets, including naive T cells. However, higher Gini-TCR indices, indicative for an enhanced TCR V&#x003B2;-repertoire skewing, were specifically associated with more differentiated CD8<sup>&#x0002B;</sup>, but not CD4<sup>&#x0002B;</sup>, T cell subsets in both ESRD patients and HI.</p>
<p>Our previous data showed that ESRD may lead to a skewed TCR V&#x003B2;-repertoire as assessed by DNA spectratyping, providing at best semiquantitative information about TCR V&#x003B2;-clonality (<xref ref-type="bibr" rid="B24">24</xref>). The current study provided more quantitative details with respect to this skewed TCR V&#x003B2;-repertoire at the T cell-subset level using the Gini-TCR index as a tool for calculating skewness (<xref ref-type="bibr" rid="B41">41</xref>) and evaluating number/type of expanded TCR V&#x003B2;-families. Higher Gini-TCR indices are indicative of a more skewed TCR V&#x003B2;-repertoire. The current study confirmed several of our previous findings. Increased skewing of the TCR V&#x003B2;-repertoire was observed for more differentiated CD8<sup>&#x0002B;</sup>, but not CD4<sup>&#x0002B;</sup>, T cells, corresponding to our spectratyping data as well as findings described by others (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B42">42</xref>). In addition to the Gini-TCR index, we calculated the number of TCR V&#x003B2;-families per patient that were expanded beyond the mean&#x02009;&#x0002B;&#x02009;2SD values of HI. This approach yielded similar results as the Gini-index but gives detailed information at the individual patient level for the different T cell subsets. For instance some patients have a large number of expanded TCR V&#x003B2;-families while others show only a few. Moreover, ESRD did not seem to affect one TCR V&#x003B2;-family in particular, indicative of expansions of different clonal origin. Altogether, using both Gini-TCR indices as well as the number of expanded TCR V&#x003B2;-families, revealed skewing to mainly occur within the CD8<sup>&#x0002B;</sup> and in particular within the CD8<sup>&#x0002B;</sup> memory T cell subset similar to what was observed before using DNA-based spectratyping on sorted T cell subsets (<xref ref-type="bibr" rid="B24">24</xref>).</p>
<p>The commercially available flow-cytometry-based assay, used to characterize the TCR V&#x003B2;-repertoire, is composed of 24 different TCR V&#x003B2;-antibodies covering about 70% of the normal human TCR V&#x003B2;-repertoire (brochure Beckman Coulter). Evaluating other TCR V&#x003B2;-families as well as TCR V&#x003B1; and TCR V&#x003B3;/V&#x003B4; families may contribute to a better understanding of the whole TCR-repertoire. In this respect, &#x003B3;&#x003B4;<sup>&#x0002B;</sup> T cells account for approximately 8% of CD3<sup>&#x0002B;</sup> peripheral blood T cells and around 6% of &#x003B3;&#x003B4;<sup>&#x0002B;</sup> T cells were observed within CD3<sup>&#x0002B;</sup>CD8<sup>&#x0002B;</sup>, but not CD4<sup>&#x0002B;</sup> T cells in HI (<xref ref-type="bibr" rid="B19">19</xref>). As frequencies of &#x003B3;&#x003B4;<sup>&#x0002B;</sup> T cells may also vary amongst individuals, it might be more accurate to evaluate the TCR V&#x003B2;-repertoire not within total CD3<sup>&#x0002B;</sup>, like performed in the current study, but within &#x003B1;&#x003B2;<sup>&#x0002B;</sup> CD3<sup>&#x0002B;</sup> T cells.</p>
<p>Interestingly, using this multiparameter flow-cytometry-based approach, we were also able to detect expanded TCR V&#x003B2;-families within the naive T cell compartment. This characteristic has, to our knowledge never been described for ESRD patients. Uremia induces a proinflammatory environment significantly affecting T cell-mediated immunity characterized by increased risk for infections (<xref ref-type="bibr" rid="B5">5</xref>) and decreased vaccination efficacy (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B43">43</xref>). We have observed that progressive loss of renal function is accompanied by a severe depletion of the naive T cell compartment and a relative shift toward more differentiated memory T cells (<xref ref-type="bibr" rid="B44">44</xref>). Naive T cells employ a mechanism referred to as homeostatic proliferation in order to maintain the naive T cell pool that is not replenished by newly developed naive T cells from the thymus due to thymic involution. Homeostatic proliferation occurs in response to homeostatic cytokines, e.g., IL-7, or low affinity self antigens presented by antigen-presenting cells (<xref ref-type="bibr" rid="B26">26</xref>). This mechanism has been described to be associated with a decline in TCR V&#x003B2;-repertoire diversity within naive T cells with increasing age (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B45">45</xref>). ESRD enhanced homeostatic proliferation of naive T cells to a similar extent as observed in older HI (<xref ref-type="bibr" rid="B12">12</xref>) and as a consequence of this compensatory mechanism, loss of TCR V&#x003B2;-repertoire diversity may also be induced by ESRD within naive CD8<sup>&#x0002B;</sup> and/or CD4<sup>&#x0002B;</sup> T cells.</p>
<p>Naive T cells are required to mount adequate immune responses to newly encountered antigens (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>). ESRD patients, with a severely depleted naive T cell compartment (<xref ref-type="bibr" rid="B44">44</xref>), are hampered in inducing adequate protection to, for example, HBV vaccination as a result of defective generation of antigen-specific memory T cells (<xref ref-type="bibr" rid="B43">43</xref>). The ESRD-associated defects in T cell composition as well as function, reminiscent of aging-associated T cell defects, led to the concept of premature T cell aging introduced in 2011 (<xref ref-type="bibr" rid="B12">12</xref>). ESRD patients have a T cell compartment that is aged by 15&#x02013;20&#x02009;years compared to their chronologic age, using age-matched HI as a reference. Consistent with premature T cell aging (<xref ref-type="bibr" rid="B12">12</xref>), we observed ESRD-associated increases in Gini-TCR indices and TCR V&#x003B2; expansions to occur already at young age.</p>
<p>Aging is known to affect TCR V&#x003B2;-repertoire diversity toward a more skewed pattern, starting from roughly 600&#x02009;&#x000D7;&#x02009;10<sup>3</sup> clonotypes detected per 10<sup>6</sup> T cells in childhood, declining by 5&#x02009;&#x000D7;&#x02009;10<sup>3</sup> clonotypes per year (<xref ref-type="bibr" rid="B25">25</xref>). Age-related effects were limited within our cohort of HI and this may be a consequence of the selection procedure applied. We did select HI with a polyclonal (i.e., non-skewed) TCR V&#x003B2;-repertoire using DNA-based spectratyping (<xref ref-type="bibr" rid="B24">24</xref>), to ensure a relatively standard healthy population to be used as reference for comparison to ESRD patients. The ESRD patient population however only consisted of individuals with an oligoclonal (skewed) TCR V&#x003B2;-repertoire. This might have resulted in an underestimation of the effect of aging on TCR V&#x003B2;-families. Likewise, our selection procedure may also explain the minimal effects of CMV in both cohorts.</p>
<p>CMV latency is known to introduce skewing of the TCR V&#x003B2;-repertoire induced by expanded CMV-specific T cell clones in both HI (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B48">48</xref>) and ESRD patients (<xref ref-type="bibr" rid="B24">24</xref>). CMV latency may result in a vast and long-lasting expansion of CMV-specific T cells (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>). Moreover, CMV latency has additional effects mainly on circulating CD8<sup>&#x0002B;</sup> T cells of ESRD patients (<xref ref-type="bibr" rid="B49">49</xref>).</p>
<p>End-stage renal disease, aging, and CMV all influenced the TCR-V&#x003B2; repertoire diversity to a different extent (<xref ref-type="bibr" rid="B24">24</xref>), however, because of different factors present in the environment, they all have their specific effect on clonotype selection. Even though these findings need to be verified in a larger cohort without preselection using DNA-based spectratyping of TCR-V&#x003B2;-repertoire, our study already shed some light on this altered TCR-V&#x003B2; repertoire at the T cell-subset level in particular with respect to ESRD.</p>
<p>Relating TCR-repertoire data to functional capacities of T cells is warranted to increase knowledge on uremia-induced T cell defects in ESRD patients. Moreover, tracking TCR clones in whole blood or tissue infiltrates may provide additional information on antigen specificity important for diagnosis of infection and allograft rejection after transplantation (<xref ref-type="bibr" rid="B50">50</xref>&#x02013;<xref ref-type="bibr" rid="B52">52</xref>).</p>
<p>In conclusion, ESRD is associated with a skewed TCR V&#x003B2;-repertoire as a result of variable TCR V&#x003B2;-family expansions, but not one TCR V&#x003B2;-family in particular. ESRD, aging and CMV latency exert their effects by influencing different TCR V&#x003B2;-families. This altered repertoire may be associated with a less broad and less diverse T cell-mediated immunity.</p>
</sec>
<sec id="S5">
<title>Ethics Statement</title>
<p>All individuals included gave informed consent and the Erasmus medical center medical ethical committee approved the study (METC number: 2012-022). It was conducted according to the principles of Declaration of Helsinki and in compliance with International Conference on Harmonization/Good Clinical Practice regulations.</p>
</sec>
<sec id="S6" sec-type="author-contributor">
<title>Author Contributions</title>
<p>LH participated in the design of the study, analyzed the data, and wrote the manuscript. MB participated in the design of the study, interpreted the data, and revised the manuscript. MK established the experimental protocol, conducted the experiments, and analyzed the data. AL participated in the design of the study, interpreted the data, and revised the manuscript. CB participated in design of the study and revised the manuscript. NL designed the study, interpreted the data, and revised the manuscript. All authors have read and approved the final manuscript.</p>
</sec>
<sec id="S7">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> The research was supported by the China Scholarship Council for funding PhD fellowship to Ling Huang (File No. 201307720043).</p></fn>
</fn-group>
<sec id="S8" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at <uri xlink:href="http://www.frontiersin.org/articles/10.3389/fimmu.2017.01826/full&#x00023;supplementary-material">http://www.frontiersin.org/articles/10.3389/fimmu.2017.01826/full&#x00023;supplementary-material</uri>.</p>
<supplementary-material xlink:href="Data_Sheet_1.xlsx" id="SM1" mimetype="applicationn/xlsx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image_1.PDF" id="SM2" mimetype="applicationn/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_1.docx" id="SM3" mimetype="applicationn/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_2.docx" id="SM4" mimetype="applicationn/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Janus</surname> <given-names>N</given-names></name> <name><surname>Vacher</surname> <given-names>LV</given-names></name> <name><surname>Karie</surname> <given-names>S</given-names></name> <name><surname>Ledneva</surname> <given-names>E</given-names></name> <name><surname>Deray</surname> <given-names>G</given-names></name></person-group>. <article-title>Vaccination and chronic kidney disease</article-title>. <source>Nephrol Dial Transplant</source> (<year>2008</year>) <volume>23</volume>(<issue>3</issue>):<fpage>800</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1093/ndt/gfm851</pub-id></citation></ref>
<ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabrizi</surname> <given-names>F</given-names></name> <name><surname>Martin</surname> <given-names>P</given-names></name></person-group>. <article-title>Hepatitis B vaccine and dialysis: current issues</article-title>. <source>Int J Artif Organs</source> (<year>2001</year>) <volume>24</volume>(<issue>10</issue>):<fpage>683</fpage>&#x02013;<lpage>94</lpage>.</citation></ref>
<ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Remschmidt</surname> <given-names>C</given-names></name> <name><surname>Wichmann</surname> <given-names>O</given-names></name> <name><surname>Harder</surname> <given-names>T</given-names></name></person-group>. <article-title>Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety</article-title>. <source>BMC Med</source> (<year>2014</year>) <volume>12</volume>:<fpage>244</fpage>.<pub-id pub-id-type="doi">10.1186/s12916-014-0244-9</pub-id><pub-id pub-id-type="pmid">25523432</pub-id></citation></ref>
<ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Principi</surname> <given-names>N</given-names></name> <name><surname>Esposito</surname> <given-names>S</given-names></name> <name><surname>Group</surname> <given-names>EVS</given-names></name></person-group>. <article-title>Influenza vaccination in patients with end-stage renal disease</article-title>. <source>Expert Opin Drug Saf</source> (<year>2015</year>) <volume>14</volume>(<issue>8</issue>):<fpage>1249</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1517/14740338.2015.1053459</pub-id><pub-id pub-id-type="pmid">26043970</pub-id></citation></ref>
<ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalrymple</surname> <given-names>LS</given-names></name> <name><surname>Go</surname> <given-names>AS</given-names></name></person-group>. <article-title>Epidemiology of acute infections among patients with chronic kidney disease</article-title>. <source>Clin J Am Soc Nephrol</source> (<year>2008</year>) <volume>3</volume>(<issue>5</issue>):<fpage>1487</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.2215/CJN.01290308</pub-id><pub-id pub-id-type="pmid">18650409</pub-id></citation></ref>
<ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Betjes</surname> <given-names>MG</given-names></name></person-group>. <article-title>Immune cell dysfunction and inflammation in end-stage renal disease</article-title>. <source>Nat Rev Nephrol</source> (<year>2013</year>) <volume>9</volume>(<issue>5</issue>):<fpage>255</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1038/nrneph.2013.44</pub-id><pub-id pub-id-type="pmid">23507826</pub-id></citation></ref>
<ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarnak</surname> <given-names>MJ</given-names></name> <name><surname>Jaber</surname> <given-names>BL</given-names></name></person-group>. <article-title>Mortality caused by sepsis in patients with end-stage renal disease compared with the general population</article-title>. <source>Kidney Int</source> (<year>2000</year>) <volume>58</volume>(<issue>4</issue>):<fpage>1758</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1111/j.1523-1755.2000.00337.x</pub-id></citation></ref>
<ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maisonneuve</surname> <given-names>P</given-names></name> <name><surname>Agodoa</surname> <given-names>L</given-names></name> <name><surname>Gellert</surname> <given-names>R</given-names></name> <name><surname>Stewart</surname> <given-names>JH</given-names></name> <name><surname>Buccianti</surname> <given-names>G</given-names></name> <name><surname>Lowenfels</surname> <given-names>AB</given-names></name> <etal/></person-group> <article-title>Cancer in patients on dialysis for end-stage renal disease: an international collaborative study</article-title>. <source>Lancet</source> (<year>1999</year>) <volume>354</volume>(<issue>9173</issue>):<fpage>93</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(99)06154-1</pub-id><pub-id pub-id-type="pmid">10408483</pub-id></citation></ref>
<ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vajdic</surname> <given-names>CM</given-names></name> <name><surname>McDonald</surname> <given-names>SP</given-names></name> <name><surname>McCredie</surname> <given-names>MR</given-names></name> <name><surname>van Leeuwen</surname> <given-names>MT</given-names></name> <name><surname>Stewart</surname> <given-names>JH</given-names></name> <name><surname>Law</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Cancer incidence before and after kidney transplantation</article-title>. <source>JAMA</source> (<year>2006</year>) <volume>296</volume>(<issue>23</issue>):<fpage>2823</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1001/jama.296.23.2823</pub-id><pub-id pub-id-type="pmid">17179459</pub-id></citation></ref>
<ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>G</given-names></name> <name><surname>Hayen</surname> <given-names>A</given-names></name> <name><surname>Chapman</surname> <given-names>JR</given-names></name> <name><surname>Webster</surname> <given-names>AC</given-names></name> <name><surname>Wang</surname> <given-names>JJ</given-names></name> <name><surname>Mitchell</surname> <given-names>P</given-names></name> <etal/></person-group> <article-title>Association of CKD and cancer risk in older people</article-title>. <source>J Am Soc Nephrol</source> (<year>2009</year>) <volume>20</volume>(<issue>6</issue>):<fpage>1341</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1681/ASN.2008090998</pub-id><pub-id pub-id-type="pmid">19406977</pub-id></citation></ref>
<ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname> <given-names>AM</given-names></name> <name><surname>Olshan</surname> <given-names>AF</given-names></name> <name><surname>Kshirsagar</surname> <given-names>AV</given-names></name> <name><surname>Edwards</surname> <given-names>JK</given-names></name> <name><surname>Nielsen</surname> <given-names>ME</given-names></name> <name><surname>Wheeler</surname> <given-names>SB</given-names></name> <etal/></person-group> <article-title>Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009</article-title>. <source>Am J Kidney Dis</source> (<year>2015</year>) <volume>65</volume>(<issue>5</issue>):<fpage>763</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1053/j.ajkd.2014.12.013</pub-id><pub-id pub-id-type="pmid">25662835</pub-id></citation></ref>
<ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Betjes</surname> <given-names>MG</given-names></name> <name><surname>Langerak</surname> <given-names>AW</given-names></name> <name><surname>van der Spek</surname> <given-names>A</given-names></name> <name><surname>de Wit</surname> <given-names>EA</given-names></name> <name><surname>Litjens</surname> <given-names>NH</given-names></name></person-group>. <article-title>Premature aging of circulating T cells in patients with end-stage renal disease</article-title>. <source>Kidney Int</source> (<year>2011</year>) <volume>80</volume>(<issue>2</issue>):<fpage>208</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1038/ki.2011.110</pub-id><pub-id pub-id-type="pmid">21525849</pub-id></citation></ref>
<ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Betjes</surname> <given-names>MG</given-names></name> <name><surname>Litjens</surname> <given-names>NH</given-names></name></person-group>. <article-title>Chronic kidney disease and premature ageing of the adaptive immune response</article-title>. <source>Curr Urol Rep</source> (<year>2015</year>) <volume>16</volume>(<issue>1</issue>):<fpage>471</fpage>.<pub-id pub-id-type="doi">10.1007/s11934-014-0471-9</pub-id><pub-id pub-id-type="pmid">25404185</pub-id></citation></ref>
<ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meijers</surname> <given-names>RW</given-names></name> <name><surname>Litjens</surname> <given-names>NH</given-names></name> <name><surname>de Wit</surname> <given-names>EA</given-names></name> <name><surname>Langerak</surname> <given-names>AW</given-names></name> <name><surname>van der Spek</surname> <given-names>A</given-names></name> <name><surname>Baan</surname> <given-names>CC</given-names></name> <etal/></person-group> <article-title>Uremia causes premature ageing of the T cell compartment in end-stage renal disease patients</article-title>. <source>Immun Ageing</source> (<year>2012</year>) <volume>9</volume>(<issue>1</issue>):<fpage>19</fpage>.<pub-id pub-id-type="doi">10.1186/1742-4933-9-19</pub-id><pub-id pub-id-type="pmid">22971545</pub-id></citation></ref>
<ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>L</given-names></name> <name><surname>Litjens</surname> <given-names>NHR</given-names></name> <name><surname>Kannegieter</surname> <given-names>NM</given-names></name> <name><surname>Klepper</surname> <given-names>M</given-names></name> <name><surname>Baan</surname> <given-names>CC</given-names></name> <name><surname>Betjes</surname> <given-names>MGH</given-names></name></person-group>. <article-title>pERK-dependent defective TCR-mediated activation of CD4&#x0002B; T cells in end-stage renal disease patients</article-title>. <source>Immun Ageing</source> (<year>2017</year>) <volume>14</volume>:<fpage>14</fpage>.<pub-id pub-id-type="doi">10.1186/s12979-017-0096-196</pub-id><pub-id pub-id-type="pmid">28642802</pub-id></citation></ref>
<ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname> <given-names>SJ</given-names></name> <name><surname>La Gruta</surname> <given-names>NL</given-names></name> <name><surname>Kedzierska</surname> <given-names>K</given-names></name> <name><surname>Thomas</surname> <given-names>PG</given-names></name> <name><surname>Doherty</surname> <given-names>PC</given-names></name></person-group>. <article-title>Functional implications of T cell receptor diversity</article-title>. <source>Curr Opin Immunol</source> (<year>2009</year>) <volume>21</volume>(<issue>3</issue>):<fpage>286</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/j.coi.2009.05.004</pub-id><pub-id pub-id-type="pmid">19524428</pub-id></citation></ref>
<ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname> <given-names>KC</given-names></name> <name><surname>Teyton</surname> <given-names>L</given-names></name> <name><surname>Wilson</surname> <given-names>IA</given-names></name></person-group>. <article-title>Structural basis of T cell recognition</article-title>. <source>Annu Rev Immunol</source> (<year>1999</year>) <volume>17</volume>:<fpage>369</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.17.1.369</pub-id><pub-id pub-id-type="pmid">10358763</pub-id></citation></ref>
<ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Dongen</surname> <given-names>JJ</given-names></name> <name><surname>Langerak</surname> <given-names>AW</given-names></name> <name><surname>Bruggemann</surname> <given-names>M</given-names></name> <name><surname>Evans</surname> <given-names>PA</given-names></name> <name><surname>Hummel</surname> <given-names>M</given-names></name> <name><surname>Lavender</surname> <given-names>FL</given-names></name> <etal/></person-group> <article-title>Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936</article-title>. <source>Leukemia</source> (<year>2003</year>) <volume>17</volume>(<issue>12</issue>):<fpage>2257</fpage>&#x02013;<lpage>317</lpage>.<pub-id pub-id-type="doi">10.1038/sj.leu.2403202</pub-id><pub-id pub-id-type="pmid">14671650</pub-id></citation></ref>
<ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van den Beemd</surname> <given-names>R</given-names></name> <name><surname>Boor</surname> <given-names>PP</given-names></name> <name><surname>van Lochem</surname> <given-names>EG</given-names></name> <name><surname>Hop</surname> <given-names>WC</given-names></name> <name><surname>Langerak</surname> <given-names>AW</given-names></name> <name><surname>Wolvers-Tettero</surname> <given-names>IL</given-names></name> <etal/></person-group> <article-title>Flow cytometric analysis of the Vbeta repertoire in healthy controls</article-title>. <source>Cytometry</source> (<year>2000</year>) <volume>40</volume>(<issue>4</issue>):<fpage>336</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1002/1097-0320(20000801)40:4&#x0003C;336:AID-CYTO9&#x0003E;3.0.CO;2-0</pub-id></citation></ref>
<ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tzifi</surname> <given-names>F</given-names></name> <name><surname>Kanariou</surname> <given-names>M</given-names></name> <name><surname>Tzanoudaki</surname> <given-names>M</given-names></name> <name><surname>Mihas</surname> <given-names>C</given-names></name> <name><surname>Paschali</surname> <given-names>E</given-names></name> <name><surname>Chrousos</surname> <given-names>G</given-names></name> <etal/></person-group> <article-title>Flow cytometric analysis of the CD4&#x0002B; TCR Vbeta repertoire in the peripheral blood of children with type 1 diabetes mellitus, systemic lupus erythematosus and age-matched healthy controls</article-title>. <source>BMC Immunol</source> (<year>2013</year>) <volume>14</volume>:<fpage>33</fpage>.<pub-id pub-id-type="doi">10.1186/1471-2172-14-33</pub-id></citation></ref>
<ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langerak</surname> <given-names>AW</given-names></name> <name><surname>van Den Beemd</surname> <given-names>R</given-names></name> <name><surname>Wolvers-Tettero</surname> <given-names>IL</given-names></name> <name><surname>Boor</surname> <given-names>PP</given-names></name> <name><surname>van Lochem</surname> <given-names>EG</given-names></name> <name><surname>Hooijkaas</surname> <given-names>H</given-names></name> <etal/></person-group> <article-title>Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations</article-title>. <source>Blood</source> (<year>2001</year>) <volume>98</volume>(<issue>1</issue>):<fpage>165</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1182/blood.V98.1.165</pub-id><pub-id pub-id-type="pmid">11418476</pub-id></citation></ref>
<ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Britanova</surname> <given-names>OV</given-names></name> <name><surname>Shugay</surname> <given-names>M</given-names></name> <name><surname>Merzlyak</surname> <given-names>EM</given-names></name> <name><surname>Staroverov</surname> <given-names>DB</given-names></name> <name><surname>Putintseva</surname> <given-names>EV</given-names></name> <name><surname>Turchaninova</surname> <given-names>MA</given-names></name> <etal/></person-group> <article-title>Dynamics of individual T cell repertoires: from cord blood to centenarians</article-title>. <source>J Immunol</source> (<year>2016</year>) <volume>196</volume>(<issue>12</issue>):<fpage>5005</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1600005</pub-id><pub-id pub-id-type="pmid">27183615</pub-id></citation></ref>
<ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname> <given-names>K</given-names></name> <name><surname>Cologne</surname> <given-names>JB</given-names></name> <name><surname>Cordova</surname> <given-names>K</given-names></name> <name><surname>Misumi</surname> <given-names>M</given-names></name> <name><surname>Yamaoka</surname> <given-names>M</given-names></name> <name><surname>Kyoizumi</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Aging-related changes in human T-cell repertoire over 20years delineated by deep sequencing of peripheral T-cell receptors</article-title>. <source>Exp Gerontol</source> (<year>2017</year>) <volume>96</volume>:<fpage>29</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="doi">10.1016/j.exger.2017.05.015</pub-id><pub-id pub-id-type="pmid">28535950</pub-id></citation></ref>
<ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>L</given-names></name> <name><surname>Langerak</surname> <given-names>AW</given-names></name> <name><surname>Wolvers-Tettero</surname> <given-names>IL</given-names></name> <name><surname>Meijers</surname> <given-names>RW</given-names></name> <name><surname>Baan</surname> <given-names>CC</given-names></name> <name><surname>Litjens</surname> <given-names>NH</given-names></name> <etal/></person-group> <article-title>End stage renal disease patients have a skewed T cell receptor Vbeta repertoire</article-title>. <source>Immun Ageing</source> (<year>2015</year>) <volume>12</volume>:<fpage>28</fpage>.<pub-id pub-id-type="doi">10.1186/s12979-015-0055-7</pub-id></citation></ref>
<ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Britanova</surname> <given-names>OV</given-names></name> <name><surname>Putintseva</surname> <given-names>EV</given-names></name> <name><surname>Shugay</surname> <given-names>M</given-names></name> <name><surname>Merzlyak</surname> <given-names>EM</given-names></name> <name><surname>Turchaninova</surname> <given-names>MA</given-names></name> <name><surname>Staroverov</surname> <given-names>DB</given-names></name> <etal/></person-group> <article-title>Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>192</volume>(<issue>6</issue>):<fpage>2689</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1302064</pub-id><pub-id pub-id-type="pmid">24510963</pub-id></citation></ref>
<ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kohler</surname> <given-names>S</given-names></name> <name><surname>Wagner</surname> <given-names>U</given-names></name> <name><surname>Pierer</surname> <given-names>M</given-names></name> <name><surname>Kimmig</surname> <given-names>S</given-names></name> <name><surname>Oppmann</surname> <given-names>B</given-names></name> <name><surname>Mowes</surname> <given-names>B</given-names></name> <etal/></person-group> <article-title>Post-thymic in vivo proliferation of naive CD4(&#x0002B;) T cells constrains the TCR repertoire in healthy human adults</article-title>. <source>Eur J Immunol</source> (<year>2005</year>) <volume>35</volume>(<issue>6</issue>):<fpage>1987</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1002/eji.200526181</pub-id><pub-id pub-id-type="pmid">15909312</pub-id></citation></ref>
<ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname> <given-names>Q</given-names></name> <name><surname>Liu</surname> <given-names>Y</given-names></name> <name><surname>Cheng</surname> <given-names>Y</given-names></name> <name><surname>Glanville</surname> <given-names>J</given-names></name> <name><surname>Zhang</surname> <given-names>D</given-names></name> <name><surname>Lee</surname> <given-names>JY</given-names></name> <etal/></person-group> <article-title>Diversity and clonal selection in the human T-cell repertoire</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2014</year>) <volume>111</volume>(<issue>36</issue>):<fpage>13139</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1409155111</pub-id><pub-id pub-id-type="pmid">25157137</pub-id></citation></ref>
<ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname> <given-names>W</given-names></name> <name><surname>Rao</surname> <given-names>S</given-names></name></person-group>. <article-title>Mechanisms underlying T cell immunosenescence: aging and cytomegalovirus infection</article-title>. <source>Front Microbiol</source> (<year>2016</year>) <volume>7</volume>:<fpage>2111</fpage>.<pub-id pub-id-type="doi">10.3389/fmicb.2016.02111</pub-id><pub-id pub-id-type="pmid">28082969</pub-id></citation></ref>
<ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Litjens</surname> <given-names>NH</given-names></name> <name><surname>de Wit</surname> <given-names>EA</given-names></name> <name><surname>Betjes</surname> <given-names>MG</given-names></name></person-group>. <article-title>Differential effects of age, cytomegalovirus-seropositivity and end-stage renal disease (ESRD) on circulating T lymphocyte subsets</article-title>. <source>Immun Ageing</source> (<year>2011</year>) <volume>8</volume>(<issue>1</issue>):<fpage>2</fpage>.<pub-id pub-id-type="doi">10.1186/1742-4933-8-2</pub-id><pub-id pub-id-type="pmid">21214947</pub-id></citation></ref>
<ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hooper</surname> <given-names>M</given-names></name> <name><surname>Kallas</surname> <given-names>EG</given-names></name> <name><surname>Coffin</surname> <given-names>D</given-names></name> <name><surname>Campbell</surname> <given-names>D</given-names></name> <name><surname>Evans</surname> <given-names>TG</given-names></name> <name><surname>Looney</surname> <given-names>RJ</given-names></name></person-group>. <article-title>Cytomegalovirus seropositivity is associated with the expansion of CD4&#x0002B;CD28- and CD8&#x0002B;CD28- T cells in rheumatoid arthritis</article-title>. <source>J Rheumatol</source> (<year>1999</year>) <volume>26</volume>(<issue>7</issue>):<fpage>1452</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">10405929</pub-id></citation></ref>
<ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wikby</surname> <given-names>A</given-names></name> <name><surname>Johansson</surname> <given-names>B</given-names></name> <name><surname>Olsson</surname> <given-names>J</given-names></name> <name><surname>Lofgren</surname> <given-names>S</given-names></name> <name><surname>Nilsson</surname> <given-names>BO</given-names></name> <name><surname>Ferguson</surname> <given-names>F</given-names></name></person-group>. <article-title>Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study</article-title>. <source>Exp Gerontol</source> (<year>2002</year>) <volume>37</volume>(<issue>2&#x02013;3</issue>):<fpage>445</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1016/S0531-5565(01)00212-1</pub-id><pub-id pub-id-type="pmid">11772532</pub-id></citation></ref>
<ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van de Berg</surname> <given-names>PJ</given-names></name> <name><surname>Griffiths</surname> <given-names>SJ</given-names></name> <name><surname>Yong</surname> <given-names>SL</given-names></name> <name><surname>Macaulay</surname> <given-names>R</given-names></name> <name><surname>Bemelman</surname> <given-names>FJ</given-names></name> <name><surname>Jackson</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Cytomegalovirus infection reduces telomere length of the circulating T cell pool</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>184</volume>(<issue>7</issue>):<fpage>3417</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.0903442</pub-id><pub-id pub-id-type="pmid">20176738</pub-id></citation></ref>
<ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gillespie</surname> <given-names>GM</given-names></name> <name><surname>Wills</surname> <given-names>MR</given-names></name> <name><surname>Appay</surname> <given-names>V</given-names></name> <name><surname>O&#x02019;Callaghan</surname> <given-names>C</given-names></name> <name><surname>Murphy</surname> <given-names>M</given-names></name> <name><surname>Smith</surname> <given-names>N</given-names></name> <etal/></person-group> <article-title>Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(&#x0002B;) T lymphocytes in healthy seropositive donors</article-title>. <source>J Virol</source> (<year>2000</year>) <volume>74</volume>(<issue>17</issue>):<fpage>8140</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1128/JVI.74.17.8140-8150.2000</pub-id><pub-id pub-id-type="pmid">10933725</pub-id></citation></ref>
<ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klarenbeek</surname> <given-names>PL</given-names></name> <name><surname>Remmerswaal</surname> <given-names>EB</given-names></name> <name><surname>ten Berge</surname> <given-names>IJ</given-names></name> <name><surname>Doorenspleet</surname> <given-names>ME</given-names></name> <name><surname>van Schaik</surname> <given-names>BD</given-names></name> <name><surname>Esveldt</surname> <given-names>RE</given-names></name> <etal/></person-group> <article-title>Deep sequencing of antiviral T-cell responses to HCMV and EBV in humans reveals a stable repertoire that is maintained for many years</article-title>. <source>PLoS Pathog</source> (<year>2012</year>) <volume>8</volume>(<issue>9</issue>):<fpage>e1002889</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1002889</pub-id><pub-id pub-id-type="pmid">23028307</pub-id></citation></ref>
<ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Litjens</surname> <given-names>NH</given-names></name> <name><surname>Huisman</surname> <given-names>M</given-names></name> <name><surname>Baan</surname> <given-names>CC</given-names></name> <name><surname>van Druningen</surname> <given-names>CJ</given-names></name> <name><surname>Betjes</surname> <given-names>MG</given-names></name></person-group>. <article-title>Hepatitis B vaccine-specific CD4(&#x0002B;) T cells can be detected and characterised at the single cell level: limited usefulness of dendritic cells as signal enhancers</article-title>. <source>J Immunol Methods</source> (<year>2008</year>) <volume>330</volume>(<issue>1&#x02013;2</issue>):<fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1016/j.jim.2007.10.013</pub-id><pub-id pub-id-type="pmid">18061610</pub-id></citation></ref>
<ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kohler</surname> <given-names>S</given-names></name> <name><surname>Thiel</surname> <given-names>A</given-names></name></person-group>. <article-title>Life after the thymus: CD31&#x0002B; and CD31- human naive CD4&#x0002B; T-cell subsets</article-title>. <source>Blood</source> (<year>2009</year>) <volume>113</volume>(<issue>4</issue>):<fpage>769</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2008-02-139154</pub-id><pub-id pub-id-type="pmid">18583570</pub-id></citation></ref>
<ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merino</surname> <given-names>J</given-names></name> <name><surname>Martinez-Gonzalez</surname> <given-names>MA</given-names></name> <name><surname>Rubio</surname> <given-names>M</given-names></name> <name><surname>Inoges</surname> <given-names>S</given-names></name> <name><surname>Sanchez-Ibarrola</surname> <given-names>A</given-names></name> <name><surname>Subira</surname> <given-names>ML</given-names></name></person-group>. <article-title>Progressive decrease of CD8high&#x0002B; CD28&#x0002B; CD57- cells with ageing</article-title>. <source>Clin Exp Immunol</source> (<year>1998</year>) <volume>112</volume>(<issue>1</issue>):<fpage>48</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1046/j.1365-2249.1998.00551.x</pub-id><pub-id pub-id-type="pmid">9566789</pub-id></citation></ref>
<ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bandres</surname> <given-names>E</given-names></name> <name><surname>Merino</surname> <given-names>J</given-names></name> <name><surname>Vazquez</surname> <given-names>B</given-names></name> <name><surname>Inoges</surname> <given-names>S</given-names></name> <name><surname>Moreno</surname> <given-names>C</given-names></name> <name><surname>Subira</surname> <given-names>ML</given-names></name> <etal/></person-group> <article-title>The increase of IFN-gamma production through aging correlates with the expanded CD8(&#x0002B;high)CD28(-)CD57(&#x0002B;) subpopulation</article-title>. <source>Clin Immunol</source> (<year>2000</year>) <volume>96</volume>(<issue>3</issue>):<fpage>230</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1006/clim.2000.4894</pub-id><pub-id pub-id-type="pmid">10964541</pub-id></citation></ref>
<ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laydon</surname> <given-names>DJ</given-names></name> <name><surname>Melamed</surname> <given-names>A</given-names></name> <name><surname>Sim</surname> <given-names>A</given-names></name> <name><surname>Gillet</surname> <given-names>NA</given-names></name> <name><surname>Sim</surname> <given-names>K</given-names></name> <name><surname>Darko</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Quantification of HTLV-1 clonality and TCR diversity</article-title>. <source>PLoS Comput Biol</source> (<year>2014</year>) <volume>10</volume>(<issue>6</issue>):<fpage>e1003646</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pcbi.1003646</pub-id><pub-id pub-id-type="pmid">24945836</pub-id></citation></ref>
<ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname> <given-names>PG</given-names></name> <name><surname>Handel</surname> <given-names>A</given-names></name> <name><surname>Doherty</surname> <given-names>PC</given-names></name> <name><surname>La Gruta</surname> <given-names>NL</given-names></name></person-group>. <article-title>Ecological analysis of antigen-specific CTL repertoires defines the relationship between naive and immune T-cell populations</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2013</year>) <volume>110</volume>(<issue>5</issue>):<fpage>1839</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1222149110</pub-id><pub-id pub-id-type="pmid">23319654</pub-id></citation></ref>
<ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Geest</surname> <given-names>KS</given-names></name> <name><surname>Abdulahad</surname> <given-names>WH</given-names></name> <name><surname>Horst</surname> <given-names>G</given-names></name> <name><surname>Lorencetti</surname> <given-names>PG</given-names></name> <name><surname>Bijzet</surname> <given-names>J</given-names></name> <name><surname>Arends</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Quantifying distribution of flow cytometric TCR-Vbeta usage with economic statistics</article-title>. <source>PLoS One</source> (<year>2015</year>) <volume>10</volume>(<issue>4</issue>):<fpage>e0125373</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0125373</pub-id></citation></ref>
<ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robins</surname> <given-names>HS</given-names></name> <name><surname>Campregher</surname> <given-names>PV</given-names></name> <name><surname>Srivastava</surname> <given-names>SK</given-names></name> <name><surname>Wacher</surname> <given-names>A</given-names></name> <name><surname>Turtle</surname> <given-names>CJ</given-names></name> <name><surname>Kahsai</surname> <given-names>O</given-names></name> <etal/></person-group> <article-title>Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells</article-title>. <source>Blood</source> (<year>2009</year>) <volume>114</volume>(<issue>19</issue>):<fpage>4099</fpage>&#x02013;<lpage>107</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2009-04-217604</pub-id></citation></ref>
<ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Litjens</surname> <given-names>NH</given-names></name> <name><surname>Huisman</surname> <given-names>M</given-names></name> <name><surname>van den Dorpel</surname> <given-names>M</given-names></name> <name><surname>Betjes</surname> <given-names>MG</given-names></name></person-group>. <article-title>Impaired immune responses and antigen-specific memory CD4&#x0002B; T cells in hemodialysis patients</article-title>. <source>J Am Soc Nephrol</source> (<year>2008</year>) <volume>19</volume>(<issue>8</issue>):<fpage>1483</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1681/ASN.2007090971</pub-id><pub-id pub-id-type="pmid">18480314</pub-id></citation></ref>
<ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Litjens</surname> <given-names>NH</given-names></name> <name><surname>van Druningen</surname> <given-names>CJ</given-names></name> <name><surname>Betjes</surname> <given-names>MG</given-names></name></person-group>. <article-title>Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes</article-title>. <source>Clin Immunol</source> (<year>2006</year>) <volume>118</volume>(<issue>1</issue>):<fpage>83</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2005.09.007</pub-id><pub-id pub-id-type="pmid">16257266</pub-id></citation></ref>
<ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname> <given-names>M</given-names></name> <name><surname>Lanzer</surname> <given-names>KG</given-names></name> <name><surname>Yager</surname> <given-names>EJ</given-names></name> <name><surname>Adams</surname> <given-names>PS</given-names></name> <name><surname>Johnson</surname> <given-names>LL</given-names></name> <name><surname>Blackman</surname> <given-names>MA</given-names></name></person-group>. <article-title>Clonal expansions and loss of receptor diversity in the naive CD8 T cell repertoire of aged mice</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>182</volume>(<issue>2</issue>):<fpage>784</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.182.2.784</pub-id><pub-id pub-id-type="pmid">19124721</pub-id></citation></ref>
<ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname> <given-names>LA</given-names></name> <name><surname>Daniel</surname> <given-names>A</given-names></name> <name><surname>Frank</surname> <given-names>I</given-names></name> <name><surname>Tebas</surname> <given-names>P</given-names></name> <name><surname>Boyer</surname> <given-names>JD</given-names></name></person-group>. <article-title>Seroprotection of HIV-infected subjects after influenza A(H1N1) vaccination is directly associated with baseline frequency of naive T cells</article-title>. <source>J Infect Dis</source> (<year>2014</year>) <volume>210</volume>(<issue>4</issue>):<fpage>646</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1093/infdis/jiu132</pub-id><pub-id pub-id-type="pmid">24610877</pub-id></citation></ref>
<ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname> <given-names>AR</given-names></name> <name><surname>Malzer</surname> <given-names>JN</given-names></name> <name><surname>Domingo</surname> <given-names>C</given-names></name> <name><surname>Jurchott</surname> <given-names>K</given-names></name> <name><surname>Grutzkau</surname> <given-names>A</given-names></name> <name><surname>Babel</surname> <given-names>N</given-names></name> <etal/></person-group> <article-title>Low thymic activity and dendritic cell numbers are associated with the immune response to primary viral infection in elderly humans</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>195</volume>(<issue>10</issue>):<fpage>4699</fpage>&#x02013;<lpage>711</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1500598</pub-id><pub-id pub-id-type="pmid">26459351</pub-id></citation></ref>
<ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>EC</given-names></name> <name><surname>Moss</surname> <given-names>PA</given-names></name> <name><surname>Frodsham</surname> <given-names>P</given-names></name> <name><surname>Lehner</surname> <given-names>PJ</given-names></name> <name><surname>Bell</surname> <given-names>JI</given-names></name> <name><surname>Borysiewicz</surname> <given-names>LK</given-names></name></person-group>. <article-title>CD8highCD57&#x0002B; T lymphocytes in normal, healthy individuals are oligoclonal and respond to human cytomegalovirus</article-title>. <source>J Immunol</source> (<year>1995</year>) <volume>155</volume>(<issue>10</issue>):<fpage>5046</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">7594513</pub-id></citation></ref>
<ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meijers</surname> <given-names>RW</given-names></name> <name><surname>Litjens</surname> <given-names>NH</given-names></name> <name><surname>de Wit</surname> <given-names>EA</given-names></name> <name><surname>Langerak</surname> <given-names>AW</given-names></name> <name><surname>van der Spek</surname> <given-names>A</given-names></name> <name><surname>Baan</surname> <given-names>CC</given-names></name> <etal/></person-group> <article-title>Cytomegalovirus contributes partly to uraemia-associated premature immunological ageing of the T cell compartment</article-title>. <source>Clin Exp Immunol</source> (<year>2013</year>) <volume>174</volume>(<issue>3</issue>):<fpage>424</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1111/cei.12188</pub-id><pub-id pub-id-type="pmid">23962178</pub-id></citation></ref>
<ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dziubianau</surname> <given-names>M</given-names></name> <name><surname>Hecht</surname> <given-names>J</given-names></name> <name><surname>Kuchenbecker</surname> <given-names>L</given-names></name> <name><surname>Sattler</surname> <given-names>A</given-names></name> <name><surname>Stervbo</surname> <given-names>U</given-names></name> <name><surname>Rodelsperger</surname> <given-names>C</given-names></name> <etal/></person-group> <article-title>TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology</article-title>. <source>Am J Transplant</source> (<year>2013</year>) <volume>13</volume>(<issue>11</issue>):<fpage>2842</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1111/ajt.12431</pub-id><pub-id pub-id-type="pmid">24020931</pub-id></citation></ref>
<ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alachkar</surname> <given-names>H</given-names></name> <name><surname>Mutonga</surname> <given-names>M</given-names></name> <name><surname>Kato</surname> <given-names>T</given-names></name> <name><surname>Kalluri</surname> <given-names>S</given-names></name> <name><surname>Kakuta</surname> <given-names>Y</given-names></name> <name><surname>Uemura</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Quantitative characterization of T-cell repertoire and biomarkers in kidney transplant rejection</article-title>. <source>BMC Nephrol</source> (<year>2016</year>) <volume>17</volume>(<issue>1</issue>):<fpage>181</fpage>.<pub-id pub-id-type="doi">10.1186/s12882-016-0395-3</pub-id><pub-id pub-id-type="pmid">27871261</pub-id></citation></ref>
<ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname> <given-names>H</given-names></name> <name><surname>DeWolf</surname> <given-names>S</given-names></name> <name><surname>Robins</surname> <given-names>H</given-names></name> <name><surname>Sprangers</surname> <given-names>B</given-names></name> <name><surname>LoCascio</surname> <given-names>SA</given-names></name> <name><surname>Shonts</surname> <given-names>BA</given-names></name> <etal/></person-group> <article-title>Tracking donor-reactive T cells: evidence for clonal deletion in tolerant kidney transplant patients</article-title>. <source>Sci Transl Med</source> (<year>2015</year>) <volume>7</volume>(<issue>272</issue>):<fpage>272ra10</fpage>.<pub-id pub-id-type="doi">10.1126/scitranslmed.3010760</pub-id></citation></ref>
</ref-list>
</back>
</article>